Pharmaceutical Technology

JULY 1, 2022

Ildong Pharmaceutical will licence a suite of Twist Bioscience's VHH antibody libraries after the two companies entered a partnership agreement. Twist's VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. .

Antibody 147

Antibody Development Licensing Licensing 147

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Production Protein Development 147

Fierce Pharma

FEBRUARY 20, 2024

After laying out plans to absorb a pair of production subsidiaries in October, Japan’s Daiichi Sankyo is doubling down on its quest to dominate the red-hot antibody-drug conjugate (ADC) field. Aiming to beef up development and manufacturing of antibody-drug conjugates, Daiichi Sankyo is plugging roughly €1 billion ($1.08

Antibody 99

Antibody Production Drugs Manufacturing 99

Pharmaceutical Technology

APRIL 23, 2024

Discover how Yuhan Corp's patent for anti-PD-L1 IgG class antibodies revolutionizes manufacturing yields. Learn about the advancements in production efficiency and potential therapeutic applications.

Antibody 130

Antibody Manufacturing Production 130

Pharmaceutical Technology

AUGUST 29, 2022

Sanyou Biopharmaceuticals and Shanghai KangaBio have signed a licencing agreement to expedite the development and innovation of the former’s monoclonal antibody drug. The latest deal will grant KangaBio an exclusive licence for the use of the antibody to carry out research, development, production and marketing of immunotherapy products.

Antibody 130

Antibody Development Drugs Production 130

Pharmaceutical Technology

JULY 13, 2023

US FDA granted the IgG1 monoclonal antibody the first qualified infectious disease product (QIDP) designation.

Antibody 130

Antibody Production 130

Pharmaceutical Technology

JUNE 10, 2024

Discover how AbCellera Biologics Inc's patented transgenic mouse with a unique LDH expression cassette revolutionizes immunoglobulin library production, enabling extended HCDR3 regions. Explore the groundbreaking genetic modifications enhancing antibody engineering.

Production 130

Production Engineer Genetics Antibody 130

Pharmaceutical Technology

NOVEMBER 27, 2022

Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.

Antibody 130

Antibody Licensing Licensing Development 130

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development 264

Development Antibody Immune Response Production 264

Pharmaceutical Technology

JULY 20, 2022

TSB Therapeutics, a joint venture (JV) majority-owned by Brii Biosciences (Brii Bio), has entered a collaboration with China Resources Pharmaceutical Commercial Group (CR Pharma) for the commercialisation of an antibody therapy, amubarvimab/romlusevimab combination, for Covid-19 in China. .

Antibody 147

Antibody Life Science Production Development 147

Pharmaceutical Technology

OCTOBER 18, 2022

Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. MGD024 is an investigational bispecific antibody that attaches to CD123 and CD3. The post Gilead partners with MacroGenics for bispecific antibody development appeared first on Pharmaceutical Technology.

Antibody 130

Antibody Development Sales Clinical Trials 130

Pharmaceutical Technology

OCTOBER 19, 2022

Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Eucure will oversee the production and delivery of the drug, while Syncromune will handle the clinical development and marketing.

Antibody 130

Antibody Licensing Licensing Containment 130

pharmaphorum

AUGUST 12, 2022

Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld. One group of Chinese researchers has reported however that BA.4

Antibody 145

Antibody Vaccination Vaccine Drugs 145

Pharmaceutical Technology

OCTOBER 12, 2022

Biotech start-up Toregem BioPharma has signed a memorandum of understanding (MoU) with WuXi Biologics to develop the monoclonal antibody, TRG035. Additionally, WuXi Biologics will help the company with the development of the anti-USAG-1 antibody for Investigational New Drug (IND) application.

Antibody 130

Antibody Development Bioassay Manufacturing 130

Fierce Pharma

OCTOBER 5, 2023

Lonza has extended a long-term collaboration with an unnamed “major global biopharmaceutical partner” to crank up commercial supply of antibody-drug conjugates at its site in Visp, Switzerland. The abrupt departure of Lonza’s CEO last month clearly hasn’t dampened the Swiss CDMO’s dealmaking prowess.

Antibody 99

Antibody Production Drugs 99

Pharmaceutical Technology

JULY 7, 2022

Brii Biosciences and TSB Therapeutics have commercially launched a long-acting neutralising antibody therapy combination, amubarvimab/romlusevimab, for Covid-19 in China. The two non-competing SARS-CoV-2 monoclonal neutralising antibodies, amubarvimab and romlusevimab are obtained from convalesced Covid-19 patients. 2 subvariants.

Antibody 264

Antibody Clinical Trials Clinical Trials Production 264

pharmaphorum

JULY 6, 2021

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. The three most common types of testing, PCR testing, antigen testing and antibody testing, have quickly become common terms in everyone’s vocabulary.

Antibody 111

Antibody Immune Response Protein Vaccine 111

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The company will also be eligible for tiered royalties as a percentage of global commercial sales of the products.

Antibody 130

Antibody Development Drugs Licensing 130

Pharma Mirror

APRIL 18, 2023

Dudley, UK, April 18th 2023: Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).

Licensing 130

Licensing Licensing Manufacturing Antibody 130

Pharmaceutical Technology

JANUARY 18, 2023

The National Medical Products Administration (NMPA) of China has approved Shanghai Henlius Biotech ’s monoclonal antibody Hansizhuang (serplulimab injection) along with carboplatin and etoposide to treat extensive stage small cell lung cancer (ES-SCLC).

Antibody 130

Antibody Drugs Production Marketing 130

Pharmaceutical Technology

JUNE 20, 2023

In a Phase III clinical trial, SKYCovione showed neutralising antibody responses against the SARS-CoV-2 parental strain. Last month, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted marketing authorisation for SKYCovione to prevent Covid-19 resulting from SARS-CoV-2 infection in people aged 18 years and above.

Vaccination 363

Vaccination Vaccine Protein Clinical Trials 363

Bio Pharma Dive

SEPTEMBER 16, 2024

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

Antibody 139

Antibody Production Drugs 139

Pharmaceutical Technology

MARCH 22, 2023

Process intensification can loosely be described as making more product with the same or fewer resources. The appeal of process intensification continues to grow in the biopharma industry as a means of not only increasing the productivity, but also improving sustainability. Existing technologies could also be run in a different way.

Production 130

Production Manufacturing Engineer Containment 130

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. These rogue antibodies blocked interferon action and were not present in patients with mild COVID-19 cases.

Antibody 135

Antibody Genetics Research In-Vitro 135

Pharmaceutical Technology

JANUARY 4, 2023

The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted clearance for Transcenta’s investigational new drug (IND) application for its TST003 to treat solid tumours. TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242

Pharmaceutical Technology

AUGUST 16, 2023

AGC has entered into an agreement with Asahi Kasei to produce clinical drug substance for antibody-based therapies at its Seattle site.

Production 130

Production Drugs Antibody 130

Pharmaceutical Technology

APRIL 10, 2023

Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061). The long-acting antibodies are obtained from B-cells that are donated by convalescent patients following Covid-19 infection.

Immune Response 264

Immune Response Antibody Vaccination Vaccine 264

Bio Pharma Dive

OCTOBER 25, 2024

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped during the third quarter.

Sales 156

Sales Vaccination Vaccine Antibody 156

Pharmaceutical Technology

MAY 22, 2023

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted an investigational new drug application (IND) for SinoMab BioScience’s SM17 to treat asthma.

Immune Response 273

Immune Response Clinical Trials Clinical Trials Antibody 273

Pharmaceutical Technology

AUGUST 1, 2023

The China National Medical Products Administration (NMPA) has accepted Astellas Pharma’s biologics licence application for zolbetuximab.

Antibody 130

Antibody Production 130

XTalks

NOVEMBER 12, 2024

Thus, to address drug-resistant infections, pharma and biotech companies are developing novel treatments such as bacteriophage therapies, immunomodulators and monoclonal antibodies. Monoclonal Antibody Therapies Monoclonal antibodies are gaining traction as targeted treatments for bacterial and viral infections.

Bacteria 110

Bacteria Life Science Vaccine Vaccination 110

XTalks

MARCH 10, 2025

The FDA has approved Celltrions Omlyclo (omalizumab-igec) as an interchangeable product to Xolair. Omalizumab is an anti-IgE antibody that works by blocking the effects of IgE, a key driver in many allergic reactions. Genentechs asthma drug Xolair (omalizumab) now faces its first competitive biosimilar.

Allergies 66

Allergies FDA Approval Antibody Trials 66

Pharmaceutical Technology

NOVEMBER 14, 2022

The antibody-drug conjugate (ADC) treatment is indicated for such patients who have previously received one to three systemic therapy regimens, irrespective of the usage of Avastin priorly. binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4.

Antibody 246

Antibody FDA Approval Clinical Trials Clinical Trials 246

Pharmaceutical Technology

MAY 8, 2023

Ei s ai and Bliss Biopharmaceutical have entered into a joint development agreement for antibody-drug conjugate (ADC), BB-1701, to treat cancers. BB-1701 comprises anti-HER2 antibody and eribulin and has a unique mechanism of action (MOA) including potent bystander effect and immunogenic cell death (ICD) activity.

Development 246

Development Antibody Clinical Trials Clinical Trials 246

Fierce Pharma

SEPTEMBER 18, 2023

After inking and expanding a biosimilar production partnership with Pfizer this summer, Korea’s Samsung Biologics is boosting yet another Big Pharma manufacturing agreement. Samsung Biologics has inked a new deal with Bristol Myers Squibb for large-scale drug substance production on an unnamed commercial cancer antibody.

Antibody 82

Antibody Manufacturing Production Drugs 82

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. It was granted based on data from the Phase III study, which demonstrated that the vaccine induced neutralising antibodies against the SARS-CoV-2 original strain.

Vaccine 298

Vaccine Vaccination Protein Medicine 298

BioPharma Reporter

OCTOBER 11, 2021

Samsung Biologics and Enzolytics have entered into a strategic CDMO partnership agreement targeting monoclonal antibody production.

Clinical Development 145

Clinical Development Development Antibody Production 145